Skip to main content
. 2023 Oct 27;8:413. doi: 10.1038/s41392-023-01663-6

Fig. 2.

Fig. 2

Treatment response and duration. a Best percentage changes from baseline in target lesions per RECIST v1.1; b best percentage changes from baseline in target lesions per mRECIST; c treatment exposure and response duration per RECIST v1.1; and d treatment exposure and response duration per mRECIST